샘플 요청 목록

 카트 문의
시장보고서
상품코드
1659419

골수증식성 질환 치료제 시장

Myeloproliferative Disorders Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 89 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 골수증식성 질환 치료제 시장은 2030년까지 129억 달러에 이를 전망

2024년에 100억 달러에 이른 것으로 추정되는 골수증식성 질환 치료제 세계 시장은 2030년에는 129억 달러에 이르고, 분석 기간인 2024-2030년간 CAGR 4.3%로 성장할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Ph+형 만성 골수성 백혈병(CML) 치료제는 CAGR 3.7%를 나타내고, 분석 기간 종료시에는 92억 달러에 이를 것으로 예측됩니다. 골수증식성 종양(MPN) 치료제 부문은 분석 기간 중에 CAGR 5.7%의 성장이 전망됩니다.

미국 시장은 26억 달러, 중국은 CAGR 6.6%로 성장할 것으로 예측

미국의 골수증식성 질환 치료제 시장은 2024년에 26억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년간 CAGR 6.6%로 성장을 지속하여 2030년까지 27억 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 2.5%와 3.3%를 나타낼 것으로 예측됩니다. 유럽에서는 독일이 CAGR 3.2%로 성장할 것으로 예측됩니다.

세계의 골수증식성 질환 치료제 시장 - 주요 동향과 성장 촉진요인 정리

골수증식성 질환 치료제 시장은 어떻게 진화하고 있는가?

골수증식성 질환(MPD) 치료제 시장은 질환의 발생률 증가, 치료 옵션의 지속적인 발전, 환자 및 의료진의 인식 제고로 인해 꾸준히 성장하고 있습니다. 암군이 포함됩니다. 이러한 질환은 혈전 및 출혈 문제, 급성 백혈병으로의 진행 등 다양한 합병증을 유발할 수 있습니다. 치료의 주요 목표는 증상 관리, 합병증 위험 감소 및 질병 진행을 늦추는 것입니다. 현재 치료법으로는 세포 환원 요법, JAK 억제제, 수혈과 같은 지지 요법이 있으며, MPD의 치료법이 확립되지 않은 현재, 치료법은 보다 표적화되고 효과적인 치료법으로 진화하고 있습니다.

골수증식성 질환 치료제 개발 동향은?

MPD 치료제 개발은 질병 진행에 관여하는 특정 분자 경로를 억제하는 표적치료제로 전환되고 있습니다. 룩소리티닙과 같은 JAK 억제제는 골수섬유증 및 기타 MPD 아형에 대한 1차 치료제로 널리 사용되고 있습니다. 이 분야의 새로운 트렌드는 JAK 억제제와 다른 새로운 약물을 병용하여 치료 효과를 높이고 환자의 생존 기간을 연장하는 병용요법 연구입니다. 또한, 분자진단학의 발전으로 MPD에서 흔히 나타나는 JAK2, CALR, MPL 등의 유전자 변이를 보다 정확하게 파악할 수 있게 되어 개인별 맞춤 치료 전략이 가능해졌습니다. 시장은 또한 질병 진행에 중요한 역할을 하는 골수 미세환경을 표적으로 하는 치료제 개발에 점점 더 집중하고 있습니다.

시장 성장을 주도하는 부문은?

약제군별로는 JAK 억제제가 골수섬유증과 다발성골수성혈소판감소증 관리에 있어 확고한 역할을 하고 있어 시장을 주도하고 있습니다. 2세대 JAK 억제제 및 다른 경로를 표적으로 하는 새로운 약물의 개발로 이 부문은 더욱 확대될 것으로 예상됩니다. 투여 경로에는 경구제와 주사제가 있으며, 사용 편의성과 환자 순응도 측면에서 경구제가 선호되고 있습니다. 주요 유통 경로는 병원 약국과 전문 약국이며, 후자는 MPD 치료의 특수성으로 인해 각광을 받고 있습니다. 지리적으로는 북미가 가장 큰 시장 점유율을 차지하고 있는데, 이는 높은 MPD 유병률, 탄탄한 의료 인프라, 혁신적인 치료법이 일찍부터 채택된 점 등이 배경이 되고 있습니다.

골수증식성 질환 치료제 시장의 성장을 가속하는 요인은 무엇인가?

골수증식성 질환 치료제 시장의 성장은 여러 요인, 특히 고령화 사회에서 이러한 질환의 유병률 증가, MPD의 조기 발견과 정확한 분류를 촉진하는 분자진단의 발전, JAK 억제제와 같은 표적 치료제 개발 및 새로운 치료 조합에 대한 지속적인 연구로 인해 치료 환경이 개선되고 환자들에게 더 나은 치료 옵션을 제공합니다. 새로운 치료법 조합에 대한 지속적인 연구로 치료 환경이 강화되어 환자들에게 보다 효과적인 선택권을 제공합니다. 유전자 검사에 기반한 맞춤의료에 대한 관심이 높아짐에 따라 보다 맞춤화되고 효과적인 치료 전략이 가능해졌습니다. 또한, 신약 임상시험의 확대와 규제 당국의 승인으로 환자들은 최첨단 치료법을 이용할 수 있게 되어 시장 성장을 가속하고 있습니다.

부문

적응증: Ph+ 만성 골수성 백혈병(CML), Ph-골수증식성 신생물(MPNs)

조사 대상 기업 예(총 34개사)

  • AbbVie, Inc.
  • Chia Tai Tianqing Pharmaceutical Group Company Limited
  • CTI BioPharma Corporation
  • Incyte Corporation
  • Italfarmaco SpA
  • Jubilant Therapeutics Inc.
  • Kymera Therapeutics
  • Merck & Co., Inc.
  • PharmaEssentia
  • Takeda Pharmaceutical Co., Ltd.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.03.14

Global Myeloproliferative Disorders Drugs Market to Reach US$12.9 Billion by 2030

The global market for Myeloproliferative Disorders Drugs estimated at US$10.0 Billion in the year 2024, is expected to reach US$12.9 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Ph+ Chronic Myelogenous Leukemia (CML) Drugs, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$9.2 Billion by the end of the analysis period. Growth in the Ph- Myeloproliferative Neoplasms (MPNs) Drugs segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 6.6% CAGR

The Myeloproliferative Disorders Drugs market in the U.S. is estimated at US$2.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Myeloproliferative Disorders Drugs Market - Key Trends and Drivers Summarized

How Is the Market for Myeloproliferative Disorders Drugs Evolving?

The market for Myeloproliferative Disorders (MPD) drugs is expanding steadily due to the increasing incidence of these conditions, ongoing advancements in treatment options, and growing awareness among both patients and healthcare professionals. MPD encompasses a group of blood cancers characterized by the excessive production of blood cells in the bone marrow, including polycythemia vera, essential thrombocythemia, and myelofibrosis. These disorders can lead to various complications such as blood clots, bleeding issues, and progression to acute leukemia. The primary goals of treatment include managing symptoms, reducing the risk of complications, and delaying disease progression. Current therapeutic options include cytoreductive therapies, JAK inhibitors, and supportive treatments like blood transfusions. With no known cure for MPD, the treatment landscape is evolving towards more targeted and effective management options.

What Are the Current Trends in Myeloproliferative Disorders Drug Development?

The drug development landscape for MPD is shifting towards targeted therapies, which focus on inhibiting specific molecular pathways involved in disease progression. JAK inhibitors, such as ruxolitinib, have gained widespread acceptance as the first-line treatment for myelofibrosis and other MPD subtypes. Emerging trends in this space include the exploration of combination therapies that pair JAK inhibitors with other novel agents to enhance treatment efficacy and extend patient survival. Additionally, advances in molecular diagnostics are allowing for more precise identification of genetic mutations, such as JAK2, CALR, and MPL, which are commonly associated with MPD, thereby enabling personalized treatment strategies. The market is also witnessing an increased focus on developing therapies that target the bone marrow microenvironment, which plays a critical role in disease progression.

Which Segments Are Driving Market Growth?

By drug class, JAK inhibitors dominate the market due to their established role in managing myelofibrosis and polycythemia vera. The development of second-generation JAK inhibitors and novel agents targeting other pathways is expected to further expand this segment. Routes of administration include oral and injectable, with oral medications preferred for their ease of use and patient compliance. Hospital pharmacies and specialty pharmacies are the primary distribution channels, with the latter gaining prominence due to the specialized nature of MPD treatments. Geographically, North America holds the largest market share, driven by a higher prevalence of MPD, robust healthcare infrastructure, and early adoption of innovative therapies.

What Factors Are Driving the Growth in the Myeloproliferative Disorders Drugs Market?

The growth in the Myeloproliferative Disorders drugs market is driven by several factors, including the increasing prevalence of these disorders, especially among aging populations, and advancements in molecular diagnostics that facilitate early detection and precise classification of MPD. The development of targeted therapies, such as JAK inhibitors, and ongoing research into new treatment combinations are enhancing the therapeutic landscape, offering patients more effective options. The rising focus on personalized medicine, supported by genetic testing, is also enabling more tailored and effective treatment strategies. Furthermore, the expansion of clinical trials and regulatory approvals for new drugs is providing patients with access to cutting-edge therapies, driving market growth.

SCOPE OF STUDY:

The report analyzes the Myeloproliferative Disorders Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Ph+ Chronic myelogenous leukemia (CML), Ph- Myeloproliferative Neoplasms (MPNs))

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie, Inc.
  • Chia Tai Tianqing Pharmaceutical Group Company Limited
  • CTI BioPharma Corporation
  • Incyte Corporation
  • Italfarmaco SpA
  • Jubilant Therapeutics Inc.
  • Kymera Therapeutics
  • Merck & Co., Inc.
  • PharmaEssentia
  • Takeda Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Global Economic Update
    • Myeloproliferative Disorders Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Advanced Therapies for Blood Cancers Spurs Growth in Myeloproliferative Disorders Drugs Market
    • Technological Advancements in Janus Kinase (JAK) Inhibitors Strengthen Business Case for Adoption
    • Growing Focus on Personalized Medicine and Mutation-Targeted Therapies Expands Addressable Market
    • Expansion of Myeloproliferative Disorders Drugs in Hematology-Oncology Practices Fuels Market Growth
    • Increasing Adoption of Combination Treatment Regimens Expands Market Opportunities
    • Technological Innovations in Epigenetic and Signal Transduction Inhibitors Propel Market Expansion
    • Rising Focus on Prolonging Disease-Free Survival and Managing Symptoms Drives Demand for Myeloproliferative Disorder Drugs
    • Growing Use of Myeloproliferative Disorder Drugs in Thrombosis Prevention and Symptom Control Expands Market Potential
    • Rising Adoption of Novel Agents in Advanced and Refractory Disease Expands Addressable Market
    • Technological Advancements in Cytokine Inhibitors and Molecularly Targeted Drugs Propel Market Growth
    • Increasing Focus on Reducing Treatment Toxicity and Enhancing Compliance Drives Adoption
    • Rising Demand for Myeloproliferative Disorder Drugs in Supportive and Palliative Care Strengthens Global Market
    • Expansion of Myeloproliferative Disorder Drugs in Community-Based and Hospital-Based Oncology Settings Expands Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Ph+ Chronic myelogenous leukemia (CML) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Ph- Myeloproliferative Neoplasms (MPNs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Myeloproliferative Disorders Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: USA 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: Canada 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • JAPAN
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: Japan 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • CHINA
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: China 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • EUROPE
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Europe 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • FRANCE
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: France 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • GERMANY
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Germany 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Italy 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: UK 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Spain 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Russia 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Australia 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • INDIA
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: India 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: South Korea 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Latin America 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Latin America 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Argentina 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Brazil 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Mexico 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Myeloproliferative Disorders Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Middle East 15-Year Perspective for Myeloproliferative Disorders Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Middle East 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Iran 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Israel 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UAE 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030
  • AFRICA
    • Myeloproliferative Disorders Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Myeloproliferative Disorders Drugs by Indication - Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Africa 15-Year Perspective for Myeloproliferative Disorders Drugs by Indication - Percentage Breakdown of Value Sales for Ph+ Chronic myelogenous leukemia (CML) and Ph- Myeloproliferative Neoplasms (MPNs) for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제